There are currently 1298 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Children's Health Care of Atlanta and Emory University Hospital/Winship Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis
NCT04891640
Recruiting
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
08/02/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Juvenile Spondyloarthritis
Register for Updates
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892
Recruiting
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/02/2024
Locations: GSK Investigational Site, Atlanta, Georgia
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
NCT05000632
Recruiting
Smoke Free SafeCare (SFSC) is a proposed braided intervention consisting of two evidence-based interventions: Some Things are Better Outside (STBO), aimed at promoting smoke free home rules, and SafeCare, aimed at reducing child maltreatment and improving mother and child outcomes. STBO is effective in creating smoke free homes and reducing second-hand smoke in low-SES (socioeconomic status) households. SafeCare is an effective parent training program that is broadly disseminated in child protec... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
08/01/2024
Locations: Georgia State University, Atlanta, Georgia
Conditions: Child Maltreatment, Smoking Behaviors
Register for Updates
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776
Recruiting
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2024
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
Register for Updates
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
NCT03611595
Recruiting
This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)
Gender:
ALL
Ages:
Between 2 years and 26 years
Trial Updated:
08/01/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Solid Tumor
Register for Updates
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NCT06271252
Recruiting
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/01/2024
Locations: Northside Hospital, Atlanta, Georgia
Conditions: Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Multiple Myeloma
Register for Updates
Genetic Collection Protocol
NCT05272319
Recruiting
This study involves the one-time collection of whole blood or saliva samples for the extraction and storage of DNA for use in ongoing and future ChiLDReN studies.
Gender:
ALL
Ages:
Between 24 hours and 25 years
Trial Updated:
07/30/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Liver Diseases
Register for Updates
InSpace Accelerated Rehabilitation Study
NCT05329584
Recruiting
This is a prospective, parallel group, open-label, multi- center, randomized study to assess two accelerated rehabilitation programs for use with the InSpace device in the treatment of full thickness Massive, Irreparable Rotator Cuff Tears (MIRCTs) performed during an arthroscopic procedure.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/30/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Rotator Cuff Tears
Register for Updates
First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
NCT05781399
Recruiting
The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailability between a tablet and suspension formulation of JNT-517 and the food effect in healthy volunteers. All participants in Part C will receive JNT-517. The goal of Part D is to assess the safety, tolera... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/27/2024
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Phenylketonuria
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/26/2024
Locations: Clinical Site, Atlanta, Georgia
Conditions: Bipolar Depression
Register for Updates
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588
Recruiting
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2024
Locations: GSK Investigational Site, Atlanta, Georgia
Conditions: Neoplasms, Head and Neck
Register for Updates
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
NCT06462586
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/26/2024
Locations: Clinical Site, Atlanta, Georgia +1 locations
Conditions: Bipolar Disorder, Manic
Register for Updates